1809249-37-3 exporter Hot sale in China CAS NO.1809249-37-3

FOB Price: USD: 11,500.00-12,500.00 /Kilogram Get Latest Price
Min.Order: 1 Kilogram
Payment Terms: L/C,T/T,
Available Specifications:
99%(1-25)Kilogram12500/Kilogram1USD99%(26-100)Kilogram11500/Kilogram26USD

Product Details

Keywords

1809249-37-3 exporter
Hot sale Remdesivir
1809249-37-3 in China

Quick Details

ProName: 1809249-37-3 exporter Hot sale in Chin...
CasNo: 1809249-37-3
Molecular Formula: C27H35N6O8P
Appearance: White solid powder
Application: Coronavirus；Covid-19
DeliveryTime: 5-7days
PackAge: 25kg/drum
Port: Any port in China
ProductionCapacity: 1 Metric Ton/Month
Purity: 99%
Storage: Room temperature
Transportation: Express/Sea/Air
LimitNum: 1 Kilogram
Moisture Content: ≤0.5%

Superiority

1809249-37-3 exporter Hot sale in China

Process Capability : Sartort Biopharma's chemists are skilled at performing complex, multi-step syntheses and producing and sell unique chemicals around the world. 1, we are able to concentracted size and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast delivery. 2, All chemicals are typically >97% ， For building blocks, The structure and purity is confirmed by NMR and LC-MS. Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorpting analysis and crystallographical methods.

Sartort Biopharma is a leading company engaging in the production of Intermediates, fine chemicals, Ionic liquids and 3D printing materials. It has such controlled subsidiaries as Sartort Pharma and Sartort Advanced Material，analytical laboratories, and an 10,000 m2 facility housing our process R&D labs, kilo lab and pilot plant, we have the skills, knowledge and experience to meet your kilo/commercial scale manufacturing needs.We would appreciate the opportunity to work with your company by providing the best quality, service, and technical support with very competitive pricing.

In China, Sartort Biopharma is the largest foreign trade exporter. 1809249-37-3 is one of our Hot saling products, not only because we have our own factory for production and our own professional team for sales, so as to ensure a stable source of supply and a relatively low ex-factory price, but also because of our Excellent product quality and outstanding quality are the main reasons why our products have been Hot saling all the time. You are welcome to buy.

Details

1809249-37-3 exporter Hot sale in China

Remdesivir (Remdesivir) is a nucleoside analog and is an inhibitor of RNA-dependent RNA polymerase (RdRp), which can inhibit viral nucleic acid synthesis and anti-virus. The current clinical Chemicalbook bed study for Ebola virus infection is in phase II. MERS-infected mice performed much better after receiving this combination therapy, with reduced virus replication and improved lung function. Recent studies have shown that Remdesivir has a certain active effect on inhibiting the new coronavirus.

Biological activity

Remdesivir (GS-5734) is a nucleoside analog with antiviral activity. In HAE cells, the EC50 value of SARSChemicalbook-CoV and MERS-CoV is 74nM. In delayed brain tumor cells, it has antiviral activity.

The EC50 value is 30 nM.

Application status

Remdesivir is a nucleotide analog prodrug. In vitro experiments and animal model data indicate that Redecive inhibits SARS (SARS coronavirus) and Middle East respiratory syndrome (MERS coronavirus) by inhibiting RNA-derived RNA polymerase (RdRp). , Chemicalbook Ebola coronavirus and many other coronaviruses. In vitro cell experiments show that the median effective concentration (IC50) of Radixivir against the new coronavirus is 0.77μmol·L-1. However, Remdesivir has not been approved for marketing in any country, and its effectiveness and safety have not been confirmed by phase III clinical trials, and only phase II clinical trials have been carried out for Ebola virus.

Product advantage introduction:

Remdesivir is a nucleoside analogue being researched by Gilead Sciences. On May 7, 2020, the Japanese government approved Gilead Sciences (GILD.US) drug Remdesivir for the treatment of new crowns Viral drugs have become the country's first officially approved drug for the treatment of new coronavirus-related diseases, and priority is given to severely ill patients.

Remdesivir has not been licensed or approved in countries other than Japan. In May 2020, Remdesivir was authorized by the U.S. Food and Drug Administration (FDA) with an emergency use authorization (EUA). Although it has not been officially approved by the FDA, its Chemicalbook has a very broad market prospect and has certain strategic drug value. Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Ebola virus, Marburg virus, and Middle East respiratory syndrome (MERS

) And atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future. At present, Remdesivir has been approved for use in various forms in 41 countries and regions including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada.


Product name	Remdesivir
Cas number	1809249-37-3
Molecular formula	C27H35N6O8P
Molecular weight	602.58
Appearance	White solid powder
Loss on drying	0.5%
Residue in ignition	≤0.1%
Individuel impurity	≤0.1%
Total impurities	≤1.0%
Specific Rotation	-19°~ -22°
Assay	98.0%~101.0%